Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Real-world effectiveness of antihypertensive drugs

J. Jaime Caro and Krista Payne
CMAJ January 25, 2000 162 (2) 190;
J. Jaime Caro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krista Payne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

James Wright and colleagues reported results of a meta-analysis of data on the effects of various antihypertensive drugs.1 Their stated purpose was to assist physicians in choosing an initial antihypertensive drug by systematically quantifying the available evidence on efficacy, defined as lowering blood pressure and preventing adverse outcomes. They did not achieve this goal, however, because they focused exclusively on clinical trial data. Although they mentioned the importance of exercising treatment decisions on the basis of the best available evidence, they failed to remind physicians that the real-world effectiveness of antihypertensive therapies is also largely a function of patient compliance. Unfortunately, although Wright and colleagues included data for study withdrawals, they did not consider that real-world compliance cannot be studied under the conditions imposed by trials.2

If they had deemed results from studies that investigated compliance with antihypertensive therapies in actual practice as additional evidence worthy of consideration, physicians would also have been informed that class-specific patterns of persistence with initial antihypertensive drug therapy have emerged.[3–6] Persistence with antihypertensive therapy, for example, is generally poor, particularly for initial therapy with older agents such as diuretics and β-blockers. Therefore, to conclude, as the authors have, that physicians should select a diuretic in the absence of contraindications ignores the best available evidence. If the ultimate goal of antihypertensive therapy is to control hypertension and to avoid cardiovascular events, then physicians must consider all available evidence. An anti-hypertensive medication is only efficacious if a patient remains on therapy, and initial choice of antihypertensive therapy appears to be a significant factor in achieving this outcome.

References

  1. 1.↵
    Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? CMAJ 1999;161(1):25-32.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Pablos-Mendéz A, Barr G, Shea S. Run-in periods in randomized trials. JAMA 1998;279:222-5.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5.
    OpenUrlAbstract/FREE Full Text
  4. 4.
    Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Ajorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10(7):697-704.
    OpenUrlCrossRefPubMed
  5. 5.
    Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160(1):31-7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1):41-6.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 2
25 Jan 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-world effectiveness of antihypertensive drugs
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Real-world effectiveness of antihypertensive drugs
J. Jaime Caro, Krista Payne
CMAJ Jan 2000, 162 (2) 190;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Real-world effectiveness of antihypertensive drugs
J. Jaime Caro, Krista Payne
CMAJ Jan 2000, 162 (2) 190;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Sex differences in the adherence of antihypertensive drugs: a systematic review with meta-analyses
  • The value of industry-sponsored studies of initial antihypertensive therapies
  • The value of industry-sponsored studies of initial antihypertensive therapies
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire